Company Encyclopedia
View More
name
C HEALTH GP
08225.HK
China Health Group Inc., an investment holding company, researches and develops drugs, bio drugs, natural drugs, and synthetic drugs in the People’s Republic of China. The company offers contracted pharmaceutical development and clinical research, and post market; and post launch market research, medical science, and medical market services. It also provides hospital management, clinical research and promotion, rehabilitation tourism, and specialty hospital services, as well as Wanquan cloud health services. In addition, the company offers pharmacodynamics and clinical research of drugs.
697.22 B
08225.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Life Sciences Tools and ServicesIndustry
Industry Ranking14/14
Industry medianC
Industry averageB
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-15.39%E
    • Profit Margin-44.23%E
    • Gross Margin64.50%A
  • Growth ScoreB
    • Revenue YoY20.79%A
    • Net Profit YoY76.64%A
    • Total Assets YoY-12.94%E
    • Net Assets YoY-12.74%E
  • Cash ScoreC
    • Cash Flow Margin-226.08%D
    • OCF YoY20.79%A
  • Operating ScoreD
    • Turnover0.25D
  • Debt ScoreB
    • Gearing Ratio28.73%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    C HEALTH GP: Guo Ruimeng has been appointed as the authorized representative

    According to the Zhitong Finance APP, C HEALTH GP announced that Executive Director Guo Ruimeng has been appointed as the company's authorized representative, effective from September 25, 2025

    Zhitong·
    HK
    08225
    +2.80%
    Zhitong·
    HK
    08225
    +2.80%

    C HEALTH GP has launched multiple AI-RWS studies, leading the new track of "AI + Clinical Research."

    C HEALTH GP successfully held the "AI-RWS Real World Research Summit" in Shanghai, launching more than ten AI-driven real-world studies focusing on adolescent mental disorders and behavioral and psychological symptoms in dementia (BPSD). The forum brought together 40 experts to build a full-cycle closed-loop research system, combining NLP and deep learning technologies to provide high-level real-world evidence. The company's strategic layout in the fields of adolescent mental disorders and dementia will further consolidate its industry-leading position

    Zhitong·
    HK
    08225
    +2.80%
    Zhitong·
    HK
    08225
    +2.80%

    C HEALTH GP released its interim results, with a profit attributable to shareholders of HKD 8.699 million, an increase of 18.31% year-on-year

    According to the Zhitong Finance APP, C HEALTH GP released its interim results for the six months ending June 30, 2025, with operating revenue of 21.62 million yuan (RMB, the same below), an increase of 18.19% year-on-year; profit attributable to shareholders of 8.699 million yuan, an increase of 18.31% year-on-year; basic earnings per share of 0.87 cents

    Zhitong·
    HK
    08225
    +2.80%
    Zhitong·
    HK
    08225
    +2.80%

    C HEALTH GP released its annual performance, with a loss attributable to shareholders of 14.519 million yuan, a year-on-year decrease of 74.97%

    C HEALTH GP released its annual performance for the year ended December 31, 2024, with operating revenue of 26.454 million yuan, a year-on-year increase of 23.47%. The loss attributable to shareholders was 14.519 million yuan, a year-on-year decrease of 74.97%, with a loss per share of 1.46 cents. The net loss for 2024 was approximately 14.519 million yuan, mainly due to a significant decrease in the provision for impairment of financial assets

    Zhitong·
    HK
    08225
    +2.80%
    Zhitong·
    HK
    08225
    +2.80%

    C HEALTH GP: Wang Dajun resigns as non-executive director

    According to the announcement from C HEALTH GP, due to the adjustment of the group's organizational structure and Mr. Wang Dajun's personal development plans and other personal arrangements, he will resign from his position as a non-executive director of the company, effective January 17, 2025. This organizational restructuring aims to optimize the group's management structure and improve operational efficiency

    Zhitong·
    HK
    08225
    +2.80%
    Zhitong·
    HK
    08225
    +2.80%
    © 2025 Longbridge｜Disclaimer